A Study of LY3556050 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-20

Study Completion Date

2020-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to learn more about the safety of LY3556050 after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3556050 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3556050 or placebo and will remain in the study for up to 31 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Effect of LY3556050 on Metformin in Healthy Participants

NCT05615467

Healthy

COMPLETED PHASE1

A Study of LY3526318 in Healthy Male Japanese Participants

NCT05580250

Healthy

WITHDRAWN PHASE1

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

NCT01376557

Type 2 Diabetes Mellitus

COMPLETED PHASE2

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

NCT00601250

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy

NCT01215097

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Part A - Parallel design. Part B - Open label design.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Part A - Double-blind. Part B - Open label.

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3556050

Administered orally.

Intervention Type DRUG

Placebo

Administered orally.

Intervention Type DRUG

Iohexol

Administered IV.

Intervention Type DRUG

Metformin

Administered orally.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males or females of nonchild bearing potential, as determined by medical history
* Have safety laboratory results within normal references ranges
* Weight at least 50 kilograms (kg)

Exclusion Criteria

* Have known allergies to LY3556050, iodine, metformin and related compounds
* Abnormal electrocardiogram (ECG) or blood pressure at screening
* Significant history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or endocrine disorders
* Show evidence of active renal disease with estimated glomerular filtration rate (GFR) \<90 milliliters per minute per 1.73 meters squared

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes